AcquisitionOther
ChemoCentryx, Inc. acquired CHEMOCENTRYX
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
ChemoCentryx, Inc. -> CHEMOCENTRYX · $4 BILLION
The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with TAVNEOS, a transformative, first-in-class treatment for ANCA-associated vasculitis, said Robert A.
Open source record (SEC) ↗